Active insulin time setting in MiniMed™ 780G: Impact on glucose control and patient perception

Abstract

Introduction

The active insulin time (AIT) is an adjustable parameter of the MiniMed™ 780G (MM780G) system. We analyze glucose outcomes and patient perception at different AIT settings.

Method

We conducted a quasi-experimental study on type 1 diabetes mellitus patients treated with MM780G, seen consecutively in our center. AIT was set at 2, 3 and 4 h consecutively, during a 2-week period each. Glucose metrics, insulin delivery and a questionnaire about patient perception were evaluated. At the end, results were discussed with the patient and the most appropriate AIT was agreed upon.

Results

A total of 58 users were included, aged 18–65 years, 58.6% of whom were women. At baseline, 2-h AIT was set in 6.70% of the patients, >2-h AIT and ≤3-h AIT in 24.67%, >3-h AIT and ≤4-h AIT in 58.62%, and >4-h AIT in 10.34%. Under the 2-h AIT, TIR increased by 2.28% and 6.35% vs 3- and 4-h AIT, respectively. The auto-correction boluses percentage was 21.19% at 2-h AIT, 16.90% at 3-h AIT and 14.40% at 4-h AIT.

A total of 41.4% of the users considered that 3 h was the AIT that most met their needs and 43.1% felt safer and less vulnerable to hypoglycemia at this setting. After trying on different AIT durations, 2 h increased from 6.7% of participants to 62%.

Conclusion

At 2-h AIT, the system delivers more auto-correction insulin and improves TIR vs 3- and 4-h AIT. Patients feel safer and less susceptible to hypoglycemia at 3-h AIT, but 2 out of 3 would rather choose the 2-h AIT after knowing glycemic outcomes.